Assessment of Vitamin D Supplementation in People with Intellectual Disability

Authors

  • Ramón Zabalza Uliazpi, Villa Careaga, Calzada vieja de Ategorrieta nº 95. 20013, San Sebastián, Spain
  • Iñaki Múgica Uliazpi, Villa Careaga, Calzada vieja de Ategorrieta nº 95. 20013, San Sebastián, Spain
  • Fernando Sistiaga Uliazpi, Villa Careaga, Calzada vieja de Ategorrieta nº 95. 20013, San Sebastián, Spain
  • Adolfo Garrido Donostia University Hospital, Biochemistry Department, Paseo Dr. Beguiristain, 20014 San Sebastián, Spain
  • José Ignacio Emparanza Donostia University Hospital, Clinical Epidemiology Unit, Paseo Dr. Beguiristain, 20014 San Sebastián, Spain
  • Paul Zubillaga Uliazpi, Villa Careaga, Calzada vieja de Ategorrieta nº 95. 20013, San Sebastián, Spain

DOI:

https://doi.org/10.6000/2292-2598.2014.02.01.6

Keywords:

Intellectual disability, cholecalciferol, Vitamin D supplementation, antiepileptics, prevention

Abstract

Vitamin D levels are often lower than recommended among certain groups, and these so-called at risk populations include institutionalised people with intellectual disabilities. The administration of vitamin D supplements does normalize these levels, but they tend to fall again when treatment is discontinued. The objectives of this study were, first, to assess whether the administration of 20,000 IU of cholecalciferol monthly and 60,000 IU quarterly over a year provide similar satisfactory results, and second, to explore whether the results are associated with following variables: sex, antiepileptic medication, being a wheelchair user or able to walk, and being a resident or day care user. The study population was composed of 204 individuals of both sexes cared for in four centres of the same institution. There were no differences between the levels reached with monthly and quarterly administration. The overall results show that, at the end of the test period, total 25(OH)vitamin D levels were <30 nmol/L in 3.5% of participants, 30 to < 50 nmol/L in 34%, 50 to <75 nmol/L in 41% and ≥75 nmol/L in 21.5%. There were significant differences between centres. We did not observe any harmful adverse effects attributable to the treatment. To conclude, we propose the continuous systematic administration of 60,000 IU of cholecalciferol every three months in this at-risk population.

References

Wacker M, Holick MF. Vitamin D - effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 2013; 5(1): 111-48. http://dx.doi.org/10.3390/nu5010111 DOI: https://doi.org/10.3390/nu5010111

Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition and dementia: a systematic review and meta-analysis. Neurology 2012; 79(13): 1397. http://dx.doi.org/10.1212/WNL.0b013e31826c197f DOI: https://doi.org/10.1212/WNL.0b013e31826c197f

Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010; 340: b5664-c111. http://dx.doi.org/10.1136/bmj.b5664 DOI: https://doi.org/10.1136/bmj.b5664

Coombs GFJ. Vitamin D. In: Elsevier Academic Press, editor. The Vitamins. Third ed. Burlington: Elsevier 2008; pp. 145-79.

Need AG, O'Loughlin PD, Morris HA, et al. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 2008; 23(11): 1859-63. http://dx.doi.org/10.1359/jbmr.080607 DOI: https://doi.org/10.1359/jbmr.080607

Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81. http://dx.doi.org/10.1056/NEJMra070553 DOI: https://doi.org/10.1056/NEJMra070553

Gómez de Tejada M, Sosa Henríquez M, et al. Documento de posición sobre las necesidades y niveles óptimos de vitamina D. Rev Osteoporos Metab Miner 2011; 3(1): 53-64.

Gertner JM, Domenech M. 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol. J Clin Pathol 1977; 30(2): 144-50. http://dx.doi.org/10.1136/jcp.30.2.144 DOI: https://doi.org/10.1136/jcp.30.2.144

Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303(18): 1815-22. http://dx.doi.org/10.1001/jama.2010.594 DOI: https://doi.org/10.1001/jama.2010.594

Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16(7): 713-6. http://dx.doi.org/10.1007/s00198-005-1867-7 DOI: https://doi.org/10.1007/s00198-005-1867-7

Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370(9588): 657-66. http://dx.doi.org/10.1016/S0140-6736(07)61342-7 DOI: https://doi.org/10.1016/S0140-6736(07)61342-7

Chel V, Wijnhoven HA, Smit JH, et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008; 19(5): 663-71. http://dx.doi.org/10.1007/s00198-007-0465-2 DOI: https://doi.org/10.1007/s00198-007-0465-2

Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326(7387): 469. http://dx.doi.org/10.1136/bmj.326.7387.469 DOI: https://doi.org/10.1136/bmj.326.7387.469

Bacon CJ, Gamble GD, Horne AM, et al. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int 2009; 20(8): 1407-15. http://dx.doi.org/10.1007/s00198-008-0814-9 DOI: https://doi.org/10.1007/s00198-008-0814-9

Hackman KL, Gagnon C, Briscoe RK, et al. Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust 2010; 192(12): 686-9. DOI: https://doi.org/10.5694/j.1326-5377.2010.tb03702.x

Ish-Shalom S, Segal E, Salganik T, et al. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008; 93(9): 3430-5. http://dx.doi.org/10.1210/jc.2008-0241 DOI: https://doi.org/10.1210/jc.2008-0241

Khaw KT, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr 1994; 59(5): 1040-4. DOI: https://doi.org/10.1093/ajcn/59.5.1040

Kilpinen-Loisa P, Arvio M, Ilvesmaki V, et al. Vitamin D status and optimal supplementation in institutionalized adults with intellectual disability. J Intellect Disabil Res 2009; 53(12): 1014-23. http://dx.doi.org/10.1111/j.1365-2788.2009.01218.x DOI: https://doi.org/10.1111/j.1365-2788.2009.01218.x

Pekkarinen T, Valimaki VV, Aarum S, et al. The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function.Clin Endocrinol (Oxf) 2010; 72(4): 455-61. http://dx.doi.org/10.1111/j.1365-2265.2009.03637.x DOI: https://doi.org/10.1111/j.1365-2265.2009.03637.x

Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339: b3692-445. http://dx.doi.org/10.1136/bmj.b3692 DOI: https://doi.org/10.1136/bmj.b3692

Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367(1): 40-9. http://dx.doi.org/10.1056/NEJMoa1109617 DOI: https://doi.org/10.1056/NEJMoa1109617

Vanlint S, Nugent M. Vitamin D and fractures in people with intellectual disability. J Intellect Disabil Res 2006; 50(Pt 10): 761-7. http://dx.doi.org/10.1111/j.1365-2788.2006.00841.x DOI: https://doi.org/10.1111/j.1365-2788.2006.00841.x

Lifshitz F, Maclaren NK. Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy. I. A survey of 288 patients. J Pediatr 1973; 83(4): 612-20. http://dx.doi.org/10.1016/S0022-3476(73)80223-9 DOI: https://doi.org/10.1016/S0022-3476(73)80223-9

Krishnamoorthy G, Nair R, Sundar U, et al. Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study. Neurol India 2010; 58(2): 213-9. http://dx.doi.org/10.4103/0028-3886.63796 DOI: https://doi.org/10.4103/0028-3886.63796

Lamberg-Allardt C, Wilska M, Saraste KL, et al. Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment. Ann Nutr Metab 1990; 34(4): 216-20. http://dx.doi.org/10.1159/000177590 DOI: https://doi.org/10.1159/000177590

Bartl R. Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment. Dtsch Med Wochenschr 2007; 132(27): 1475-9. http://dx.doi.org/10.1055/s-2007-982057 DOI: https://doi.org/10.1055/s-2007-982057

Downloads

Published

2014-05-06

How to Cite

Zabalza, R. ., Múgica, I. ., Sistiaga, F., Garrido, A., Emparanza, J. I. ., & Zubillaga, P. (2014). Assessment of Vitamin D Supplementation in People with Intellectual Disability . Journal of Intellectual Disability - Diagnosis and Treatment, 2(1), 46–53. https://doi.org/10.6000/2292-2598.2014.02.01.6

Issue

Section

General Articles